Key Takeaways Bristol Myers' Growth Portfolio has stabilized revenues amid generic pressure on older drugs.Opdivo leads sales, with Qvantig's strong uptake fueling mid-to-high single-digit 2025 growth.Newer drugs like Reblozyl, Camzyos, and Breyanzi are driving top-line gains despite legacy declines.Bristol Myers’ (BMY) Growth Portfolio, comprising drugs like Opdivo, Reblozyl, Breyanzi, Camzyos and Opdualag, has stabilized its revenue base amid generic competition for its legacy drugs.Among these, immuno-on ...